Table 3 Severity of Illness and outcomes of COVID-19 patients and controls.
Clinical status | Controls N = 51 | COVID-19 N = 90 | p-value |
|---|---|---|---|
Initial respiratory status | |||
Highest level of supplemental oxygen in the first 3 h | 0.2 | ||
HFNC/NRB/NIV mechanical ventilation | 2 (3.9%) | 8 (8.9%) | |
Mechanical ventilation | 2 (3.9%) | 4 (4.4%) | |
Nasal cannula | 11 (22%) | 30 (33%) | |
None | 36 (71%) | 48 (53%) | |
CXR results at admission | < 0.001 | ||
Bilateral infiltrates | 6 (13%) | 58 (64%) | |
Clear | 26 (58%) | 10 (11%) | |
Pleural effusion | 0 (0%) | 4 (4.4%) | |
Unilateral infiltrates | 6 (13%) | 0 (0%) | |
Day 1 severity of illness (median, IQR) | |||
SOFA score | 1.0 (0.0, 3.0) | 2.0 (1.0, 5.0) | 0.001 |
Complications and clinical outcomes | |||
Thromboembolic event | 2 (3.9%) | 11 (12%) | 0.13 |
Respiratory co-infection | 16 (31%) | 20 (22%) | 0.3 |
Acute respiratory distress syndrome (ARDS) requiring intubation | 0 (0%) | 36 (40%) | < 0.001 |
Acute kidney injury (AKI) stagea | < 0.001 | ||
0 | 48 (94%) | 49 (60%) | |
1 | 2 (3.9%) | 11 (14%) | |
2 | 1 (2.0%) | 5 (6.2%) | |
3 | 0 (0%) | 16 (20%) | |
In-hospital mortality | 5 (9.8%) | 19 (21%) | 0.14 |
